Real-world evidence derived from electronic health records (EHRs) is increasingly recognized as a supplement to evidence generated from traditional clinical trials. In oncology, tumor-based Response Evaluation Criteria in Solid Tumors (RECIST) endpoints are collected in clinical trials. The best approach for collecting similar endpoints from EHRs remains unknown.
comprehensive context. RECIST cannot adequately assess cancer progression in EHR-derived data due to missing data and lack of clarity in radiology reports. We found a clinician-anchored approach supported by radiology report data to be the optimal, and most practical, method for characterizing tumor-based endpoints from EHR-sourced data.
Introduction
In parallel with expanding treatment options for cancer patients and new scientific paradigms, clinical trials have become increasingly complex. However, patient outcomes remain the benchmark by which new cancer interventions are measured. The efficacy measurement of an intervention in a clinical trial, however, may not directly translate into effectiveness measured in real-world settings [1] . Real-world evidence (RWE) sources, including data derived from electronic health records (EHRs), are a valuable resource to understand the experience of cancer patients treated in the real world to augment insights from traditional clinical trials [2, 3] . RWE can be leveraged to improve therapy development programs by increasing the external validity of evidence available to support point-of-care treatment decisions [4, 5] . The key to fully unlocking the value of the EHR for these purposes is reliable and obtainable outcome metrics; however, it is unknown whether traditional cancer endpoints other than mortality can be gleaned from EHR data. In particular, we need to determine whether we can apply traditionally defined clinical trial tumor endpoints to EHR data, or whether new definitions of endpoints are needed.
Endpoints based on changes in tumor size are often utilized in solid tumor clinical trials to provide measures of treatment efficacy [6, 7] . Radiographic images are typically evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) and are often reviewed by an independent central committee to improve objectivity of tumor assessments [8, 9] . RECIST uses radiographic evidence about changes in the size of designated tumors over time ("target lesions") combined with the presence or absence of new tumors to map to categories describing the patient's disease status: "tumor response," "stable disease," or "tumor progression."
Routine clinical practice follows a similar thread of logic for assessment of response to therapy. Dynamics of tumor burden are often grouped into three main categories: "improved" (i.e., "response"), "no change" (i.e., "stable disease"), or "worse" (i.e., "tumor progression").
Determination of these outcomes is based on periodic evaluation of a variety of clinical parameters assessed with a range of methods (e.g., radiology, physical exam, biomarkers, pathology specimen, patient-reported concerns) and summarized in the clinical notes.
Depending on the clinical context, EHR documentation of changes in one or more of these parameters may reflect the outcome of an intervention.
Outcomes data within an EHR are likely composite interpretations of information on the dynamics of tumor burden, quality of life metrics, and other quantitative and qualitative assessment and test results. The richness of EHR data presents significant opportunities to develop outcome metrics specific to real-world data but may also add challenges to the determination and interpretation of real-world outcomes. To further complicate outcome determination in an EHR, the relevant data may reside within sources that are structured (i.e., data that are highly organized, such as white blood cell count) or unstructured (e.g., free text clinical notes or PDFs of radiology or biomarker reports). In other words, the EHR holds data about the effectiveness of an intervention but does so in a manner different than a clinical trial dataset. We may need to make sense of the available EHR data in a different way, likely culling it through manual data curation by trained abstractors following precise, pre-defined policies and procedures, through computer-based algorithms mimicking this approach or a combination of both.
Among these evidence sources available in the EHR, which is best to anchor cancer outcomes against? Radiology reports may not consistently include declarative assessments of response that fit in the RECIST framework. On the other hand, clinician assessments (e.g., radiology "overall impressions" or oncology note "assessment and plans"), findings (e.g., physical exams) and results (e.g., tumor markers) are often documented in the EHR, especially when they inform treatment decisions. Therefore, using clinician notes may serve as an alternative or as a supplement to radiology reports to curate cancer outcomes from EHR data.
Our purpose was to identify a practical and efficient method for large-scale abstraction of data for estimation of cancer outcomes from the EHR. Due to the variety of formats and locations in which documentation of outcomes assessments may exist in the EHR, the abstraction approach used to accomplish this goal must: (1) be applicable across multiple EHR systems; (2) be amenable to manual and/or electronic abstraction from unstructured documents; (3) accommodate the nuances of clinical judgement; (4) be reliable despite the possibility of missing data points; and, (5) be efficient to support scaling in order to enable endpoint assessments for large cohorts.
We anticipated that traditional clinical trial approaches to collecting endpoints, such as cancer progression, may need to be modified for the unique features of EHR data. We tested this hypothesis in a preliminary experiment in a small cohort of patients with advanced non-small cell lung cancer (aNSCLC). We then compared several alternative approaches for abstraction of cancer progression events from the EHR in a larger cohort of aNSCLC patients.
Methods
We conducted experiments to answer the following research questions: (1) can RECIST criteria be feasibly applied to EHR data to assess cancer progression, and (2) what are potential alternate abstraction approaches and how do they perform?
Data sources
The overall cohort was selected from Flatiron Health's longitudinal EHR-derived database, which, at the time of this study, included over 210 cancer clinics representing more than 1.2 million active patients across the United States. We identified more than 120,000 and 25,000 patients diagnosed with lung cancer and aNSCLC, respectively. The majority of patients were treated in the community oncology setting. The clinics included in this study used a variety of EHR systems. Demographic, clinical, and outcomes data were extracted out of the source EHR, which included structured data and unstructured documents. To create the database, we aggregated, normalized, and harmonized patient level data. Data were processed centrally and stored in a secure format and environment. Structured data (e.g., treatments, labs, diagnosis codes) were mapped to standard ontologies. Dates of death were obtained from a composite mortality variable comprised of the EHR structured data linked to commercial mortality data and the Social Security Death Index [10] . Unstructured data (e.g., clinician notes, radiology reports, death notices) were extracted from EHR-based digital documents via "technology-enabled" chart abstraction [11] . Every data point sourced from unstructured documents was manually reviewed by trained chart abstractors (clinical oncology nurses and tumor registrars, with oversight from medical oncologists). Quality control was conducted for this dataset, including duplicate chart abstraction of a sample of abstracted variables as well as logic checks based on clinical and data considerations.
Availability of data and materials
The data that support the findings of this study are available from Flatiron Health, but restrictions apply to the availability of these data, which are subject to the de-identification requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and implementing regulations, as amended. Practically speaking, in order to share select data and data elements, it is necessary to first define the methods of storage, transmission, access rights, and the scope of intended use prior to making any such data available, and an agreement memorializing the same and applicable re-identification restrictions are required for the purposes of ensuring compliance with the data license, de-identification, data protection specifications, and requirements under HIPAA. Please refer any questions or requests regarding data used in this manuscript to Dr. Amy Abernethy ( amy@flatiron.com ).
Study design and data collection
This retrospective observational study evaluated methods to assess cancer progression from EHR data through two objectives (Fig 1): (1) to evaluate the feasibility of a RECIST approach (Experiment 1) and (2) if a RECIST approach is not feasible, to evaluate three alternative non-RECIST abstraction approaches (Experiment 2). To assess the feasibility of the RECIST approach (Experiment 1), 26 patients were randomly selected from those meeting the inclusion criteria. The sample size was chosen to achieve expected theme saturation consistent with an initial feasibility study [12, 13] . To study the non-RECIST abstraction approaches (Experiment 2), 200 patients were randomly selected from those meeting the inclusion criteria. The sample size was chosen to balance feasibility and the need for a sufficient number of progression and death events to inform descriptive analyses.
Experiment 1: Feasibility of RECIST criteria
To determine if the data elements required for RECIST version 1.1 [9] evaluation could be abstracted from patient charts, we evaluated the radiology reports in the EHR for the baseline and first treatment response imaging assessment after initiation of first line (1L) systemic therapy. Radiology reports were evaluated for explicit descriptions of "target lesions"
as required by RECIST. The subgroup of patients for whom an explicit description of target lesions was not found were also evaluated with a more lenient approach in which abstractors identified target lesions from the available radiology reports. Lesions at least 1 cm in size were classified as measured if their size was numerically documented in the radiology report. The RECIST approach was determined to be potentially feasible for a patient if: (1) their baseline scan was conducted within two months prior to the referenced 1L therapy start date; (2) their initial follow-up scan was performed at least 28 days after the therapy start date; (3) documentation indicated that the patient's follow-up scan was compared to the baseline scan; (4) documentation existed for lesion measurements on both the baseline and follow-up scans;
and (5) all measured and non-measured lesions were specifically described in each imaging report. Although RECIST can be applied to multiple imaging modalities (e.g., CT, MRI, etc.), CT is preferred in oncology for evaluation of the lung [9] . Therefore, in the context of this experiment, we focused on CT and PET/CT including the chest when evaluating radiology reports. Additional evaluation for specific RECIST version 1.1 criteria, such as measurement of longest diameter for tumors and short-axis for lymph nodes, were excluded from this feasibility experiment with the intention of adding such criteria if RECIST were found to be feasible.
Experiment 2: Comparison of different abstraction methods for assessing real-world cancer progression
Three approaches for determining real-world cancer progression were used to abstract outcomes data from each patient's chart: (1) A radiology-anchored approach; (2) a clinician-anchored approach; and (3) a combination of both. The radiology-anchored approach is conceptually similar to RECIST in that it focuses on changes in tumor burden observed by imaging. In contrast to RECIST, the radiology-anchored approach is optimized for the type of radiological evidence sources routinely found in EHR data (e.g., impression section within radiology reports). Reports from any imaging modality were considered. The clinician-anchored approach was conceptually focused on the clinician as the synthesizer of signals from the entire patient's chart. The combined approach considers both radiology reports and the clinician's synthesis: the date of progression is determined by the earliest source document for the event.
Definitions of each approach, evidence sources evaluated, and the logic for calculating progression dates were defined according to Table 1 . Each approach also considered pathology reports as potential evidence for progression. However, there were no instances of pathology reports preceding radiology reports in the cohort analyzed for this study. In addition, there were no instances of conflicting information between radiology and pathology reports. For simplicity of presentation, pathology reports were excluded from this description as a potential evidence source.
Analysis
For Experiment 1, descriptive statistics (frequencies and percentages) were calculated for patients that met the RECIST feasibility criteria described above. Results were summarized for the percentage of cases that met all criteria, under both the strictest definition requiring explicit mention of target lesions, as well as the more lenient definition.
For Experiment 2, demographics, clinical and tumor characteristics, and treatment types were summarized using descriptive statistics (medians and interquartile ranges or frequencies and percentages, as appropriate). Progression events within the first 14 days of the start of 1L therapy were excluded from all calculations as they occurred too early to reflect treatment effectiveness.
We compared the three pre-defined data abstraction approaches to assess cancer progression from RWD as per Fig 1. For each of the three abstraction approaches, the proportion of patients with a progression event were computed with accompanying 95% confidence intervals (CIs). The concordance of progression events and associated dates were assessed across abstraction approaches. Discordant cases were reviewed to determine the source of the discrepancies. Among patients with at least one progression event, we assessed the frequency (95% CIs) of near-term (within 15 days prior and up to 60 days after the progression date) clinically relevant downstream events, defined as death, start of new therapy line (second or subsequent lines), or therapy stop. The time window was selected to allow for short delays in documentation of cancer progression that might occur when clinician notes were the only source of evidence (15 days prior) and a clinically relevant follow-up period for near-term events appropriate for aNSCLC (60 days after).
Time-to-event analyses for PFS and Time to Progression (TTP) based on real-world data (RWD, specifically rwPFS and rwTTP) as well as overall survival (OS) were performed using standard Kaplan-Meier methods [14] . The index date was defined as the date of 1L therapy start, and the event date was defined for each outcome: the date of the first progression event 
Results

Experiment 1: Feasibility of RECIST criteria
In Experiment 1, a cohort of 26 aNSCLC patients was evaluated for the feasibility of the RECIST approach (Fig 2) . When using a strict definition of RECIST that required radiologist-defined target lesions, none of the patient charts (0%) yielded data suitable for assessing cancer progression. When more lenient criteria were applied that did not require explicit mention of target lesions, only 15 charts (58%) had radiology reports describing appropriate scans available for any type of RECIST assessment. Of these, only 8 (31% of Experiment 1 cohort) demonstrated evidence of direct comparison of all measured key lesions between two timepoints. Even fewer (6, 23% of Experiment 1 cohort) had evidence that all non-measured key lesions were specifically followed between the two timepoints. Due to the lack of feasibility and very low completeness (0-23%, depending on requirement for explicit documentation of key lesions), endpoints obtained from the RECIST approach were not further analyzed or compared to the other abstraction approaches. a Appropriate scans were defined as a baseline scan (PET/CT or CT chest) within 2 months prior to therapy start AND a scan (PET/CT or CT chest) to follow-up response at least 28 days after therapy start.
b To be "directly followed," radiology reports needed to sequentially describe all documented lesions of >1 cm to track changes in size.
Experiment 2: Comparison of different abstraction methods for assessing real-world cancer progression
The study cohort for Experiment 2 consisted of 200 patients, for whom demographic and clinical characteristics are described in Table 2 . The median age at advanced diagnosis was 66 years, half were women, 63% were stage IV at diagnosis, most had non-squamous cell histology (73%), and most had a history of smoking (85%). In the majority of patients (N=173, 87%) both radiology-and clinician-anchored approaches identified at least one progression event per patient. In addition to those events identified by both approaches, 7 patients (4% of the Experiment 2 cohort) had radiology-anchored progression events without confirmation in a clinician note, leading to a total of 180 patients with a radiology-anchored progression event (90%). Of those seven cases without clinician confirmation, the discordant information could be attributed to one of two reasons: (1) the radiology report was the last available document in the chart and the clinician assessment did not exist or was unavailable in the chart (5/7), signifying possible patient death, pending clinical visit, referral to hospice, or loss to follow-up, or (2) there was disagreement between the radiology report and the assessment in the clinician note (2/7). In both of these discordant cases, the radiology report recorded progression, but the clinician determined stable disease For the 173 patients where a progression event was identified by both the radiologyand clinician-anchored approaches, progression dates matched between the two approaches for 156 patients (90%). Among the 17 patients (10%) with differing progression event dates, the radiology-anchored approach identified an earlier progression date in almost all cases (N=16, 93%). In all 16 cases, the clinician made a determination of stable disease immediately following the radiology-anchored progression event but subsequently documented a progression event. In the one final discordant case, the clinician-anchored progression event did not have a corresponding scan documented in the chart.
The association between cancer progression and near-term downstream events (15 days prior up to 60 days after), including treatment stop, treatment change, or death, is displayed in Table 3 c Includes only patients with an observed death and a cancer progression event preceding death (N=112 for the clinician-anchored approach;
N=113 for the radiology-anchored and the combined approach).
Similar inter-rater agreement was observed across abstraction approaches (Table 5 ). In 96% to 98% of cases, depending on approach, abstractors agreed on the presence or absence of a first progression event. Overall agreement was also similar for all approaches, ranging from 71% to 73% when 30-day windows between progression event dates were allowed. When considering only cases where both abstractors agreed that at least one progression event occurred (N=48, 49), the progression event dates were within 30 days of each other in 69% to 71% of patients. Qualitative feedback revealed a strong abstractor preference for the clinician-anchored abstraction approach because it afforded a more comprehensive context. One abstractor reported that the clinician-anchored approach "provide[s] a true comparison of the scan results and guide to overall patient treatment." Abstractors also reported the clinician-anchored approach to be faster and more straightforward compared to the radiology-anchored approach.
Discussion
Real-world research based on EHR data requires validated approaches to abstract outcomes in order to glean meaningful insights and ensure that outcomes are consistently described across different locations and studies. What we really want to know about an intervention is if the patient is "improved," "worse," or "unchanged." Many proxies have been proposed to answer this question. In prospective clinical trials, RECIST measurement of tumor size on imaging is a common metric. However, it was unknown if the language of clinical trial endpoints could be directly translated to routine clinical care. In addition, abstraction of outcomes from the EHR needs to facilitate, rather than hinder, research on large, contemporary cohorts. Therefore, we evaluated four approaches, one RECIST-based and three non-RECIST-based, to identify a feasible method suitable for large-scale abstraction of cancer progression from EHRs.
We found that it is not feasible to use standard, or even lenient, RECIST criteria to abstract cancer progression from the EHR. RECIST cannot be applied to EHR-based RWD because outcomes are missing at least 75% of the time. This finding is not surprising given that in the clinical trial setting collection of RECIST data requires enormous resources.
Given the infeasibility of RECIST for ascertaining real-world progression, we tested and compared three alternative approaches to define cancer progression from the EHR using technology-enabled human curation (Table 1 [15, 16] . And, correlations between rwPFS/rwTTP and OS shown here are consistent with, or higher than, results from clinical trials [15, 17, 18] . Given our reliance on RECIST in clinical trials, one might anticipate that the radiology-anchored abstraction approach would be most reliable;
however, the clinician-anchored approach was similarly reliable and abstractor feedback indicated that it may be more scalable. This similar reliability between approaches may be due to the overlap between clinician and radiology assessments of disease progression in the real-world setting.
Modest differences in rwPFS for the two methods reflect differences in the underlying conceptual structure. More progression events were identified in the radiology-anchored approach, but the clinician-anchored approach was more likely to be associated with a treatment change or death. This finding suggests that the clinician may be synthesizing information and adjudicating potentially conflicting findings. Median rwPFS was approximately two weeks shorter for the radiology-anchored approach when compared with the clinician-anchored approach, likely because imaging often precedes a clinician visit and/or assessment in real-world settings. However, modest differences and overlapping confidence intervals preclude any strong conclusions. Importantly, no meaningful differences between approaches were observed for the association between rwPFS and OS in this cohort. In this study, we identified a clinician-anchored cancer progression abstraction method to be the most practical approach for assessment of tumor-based endpoints derived from information in EHRs, with radiology and pathology reports serving as corroborating evidence.
The clinician-anchored approach is based on clinician summaries as the first source of evidence, a concept in line with how EHRs are used by clinicians. When compared with RECIST-based criteria, where even the most lenient interpretation leads to an untenable amount of missing data for most analyses, the clinician-anchored approach yields much more complete endpoint information across patients. The radiology-anchored approach was developed to align conceptually with the perspective of RECIST, directing abstractors to consider radiology reports as the primary source of truth. Based on our results, the radiology-anchored approach is reasonable as well. However, the radiology-anchored approach is potentially less scalable, at least when medical records are sourced from the community oncology setting, where the majority of patients in this cohort received treatment. Further, it is plausible the radiology-anchored approach may not perform as well in situations where determination of progression is more often based on non-radiologic findings: examples include findings manifest on physical exam, symptom history, biomarker evidence, and for care in resource-or access-limited settings.
One might question why we deemed the RECIST-based approach infeasible after only 26
patients. We applied the saturation sampling method used in qualitative research [13, 14] . The goal of our study was to evaluate whether adequately-complete outcomes data could be generated from the EHR applying the rules of RECIST. Even if we set a very lenient feasibility threshold of 75% completeness for abstraction of progression events by RECIST, it became obvious after 20 charts that the results fell far short of this minimum. We continued to enrich the sample to 26 and the poor data completeness persisted.
When measuring cancer progression using the approach outlined here, there are several limitations to consider. First, this proposed approach is susceptible to several sources of subjectivity, including that of radiologists, clinicians, and abstractors. However, the analysis results are encouraging in that they show rwPFS correlates with OS in ways similar to RECIST-based PFS, and the correlation is also similar between the radiology-and clinician-anchored approaches. We implemented clear instructions and trainings to abstractors to reduce this potential source of subjectivity during the abstraction process. Second, although similar inter-rater reliability was observed across approaches, further work, including additional training and abstractor experience with the approach, could improve reliability.
More broadly, there are additional limitations to consider when applying this work across other settings. First, application to other diseases beyond aNSCLC needs to be tested;
there may be differences in assessment cadence or availability of biomarker data, as well as fundamental difference in disease course and treatment pace. These potential differences mean that we must develop a set of rules for reconciling conflicting data about progression as well as incorporation of additional data sources. Second, our work predominantly included EHR data generated in the community oncology setting with few academic medical centers.
Documentation and treatment patterns may differ across treatment settings, limiting the generalizability of these results beyond the community oncology setting. Third, whether this approach will hold true for other real-world endpoints such as tumor response will require further examination. Lastly, any approach utilizing time-dependent endpoints is susceptible to bias due to data missingness or the frequency of assessments. This is most likely to be the case if assessment frequency is unbalanced across treatment groups and requires further study to characterize the extent of potential bias.
Based on these findings, we foresee two important next steps. In order to fully harness the potential value of EHR data, outcome measures tailored to the unique features of the data source are needed. Once those outcome measures are developed, such as the methodology for abstraction of cancer progression described here, a comprehensive validation framework must be established to enable robust and standardized characterization of such approaches. Second, we need to tailor and expand this outcomes development and validation approach to different contexts and cancer types. It is also important to explore the broader opportunities to assess other outcome metrics suitable for the real-world setting, for example, quality of life. This study lays the foundations upon which to build endpoint measures suited for RWD/RWE research.
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